Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform

Project Summary Isabl Inc. is a Memorial Sloan Kettering Cancer Center spin out, aiming to launch a cancer whole genome and transcriptome sequencing (cWGTS) diagnostic test for pediatric and rare cancer patients. The product of this SBIR is Isabl GxT, a precision medicine platform that incorporates cWGTS data into a robust data science framework to enable clinically actionable reporting in a clinically relevant timeframe and facilitate novel biomarker discovery in oncology. Isabl has generated significant feasibility and clinical utility data and obtained breakthrough device designation by the FDA. The aims of this project are: 1) perform analytical and clinical validity studies, 2) develop a commercial grade clinical bioinformatics platform, and 3) extend utility of the existing test to additional biospecimen types. The long-term objective is to empower oncology with one comprehensive cancer test.